Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for some patients with hematologic malignancies and bone marrow failure syndromes.1 More than 20,000 HSCTs are performed in the US annually and the number of transplants is only expected to increase.2 Advances in transplantation medicine has significantly reduced the burden of complications, physical symptoms and decreased mortality after a transplant.3 However, psychiatric comorbidities remain prevalent and untreated psychiatric symptoms significantly undermine health outcomes in this population.4 Consultation-Liaison (CL) Psychiatrists are experts at evaluating and managing psychiatric comorbidities in the medically ill. Hence, all CL psychiatrists must be familiar and up-to-date with the ongoing evidence on effectively assessing and managing risk and psychiatric symptoms in HSCT patients.
This interactive clinical workshop, led by four CL psychiatrists in major academic cancer centers around the country who care for HSCT patients, will present clinical cases to demonstrate an effective approach to evaluating and managing psychiatric symptoms in the HSCT population. Dr. Lokko Amonoo will provide a broad overview of the HSCT process and the prevalent psychiatric comorbidities (20 minutes) Dr. Lahijani will discuss approaches for evaluating and assessing psychiatric symptoms (20 minutes), Dr. Knight will review the approaches to neuroimmunologic risk of psychiatric pathology (20 minutes), and Dr. Rueda-Lara will discuss the pharmacological and non-pharmacological management strategies for psychiatric illness (20 minutes). The last 5-minutes of each talk will be dedicated to content specific Q & A. Finally, Dr. Lokko Amonoo will moderate the last 10 minutes for general Q&A from the audience.